Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

100%

5 of 5 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 4

3(42.9%)

Phase 1

2(28.6%)

Phase 3

1(14.3%)

Phase 2

1(14.3%)

7Total

Phase 4(3)

Phase 1(2)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01438853Phase 1Completed

Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome

Role: collaborator

NCT00264849Phase 4Completed

Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma

Role: collaborator

NCT00267202Phase 4Completed

Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

Role: collaborator

NCT00500539Phase 3Completed

Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.

Role: collaborator

NCT00624832Phase 4Completed

A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels

Role: collaborator

NCT00441818Phase 1Unknown

Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma

Role: lead

NCT00089700Phase 2Unknown

TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1

Role: lead

All 7 trials loaded